Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Rhea-AI Summary

Hologic (NASDAQ: HOLX) will showcase new breast health technologies at RSNA 2024 in Chicago, December 1-5. The company will unveil the Envision™ Mammography Platform, featuring a 2.5-second scan time and tilt positioning for enhanced patient comfort. Additionally, Hologic will introduce its Genius AI® Detection PRO solution, an advanced cancer screening technology that improves accuracy and efficiency through deep-learning algorithms.

The company will present study results showing their AI Detection 2.0 software performs consistently across diverse patient populations. At Booth #1919, Hologic will display their complete portfolio of breast imaging and surgery solutions, including recently acquired Endomag wireless breast surgery localization products.

Positive

• Introduction of new Envision™ Mammography Platform with industry-leading 2.5-second scan time
• Launch of next-generation Genius AI® Detection PRO solution with improved accuracy
• Received Excellence in Imaging Informatics Award from American Board of Imaging Informatics

Negative

• None.

Leader in Women’s Health Will Unveil Groundbreaking Innovations With a Focus on Imaging Solutions and Artificial Intelligence

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110^th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago on December 1-5. On the show floor and during multiple workshops, Hologic will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection.

Experience the cutting-edge Envision™ Mammography Platform (Graphic: Business Wire)

For the first time, attendees can experience the cutting-edge Envision™ Mammography Platform, which offers patients a high-speed Hologic 3D™ mammogram with an industry-leading 2.5-second scan time.^1* This next-generation technology provides a more comfortable exam with tilt positioning, adapting to patients rather than the other way around.² As the first FDA-approved mammography technology of its kind,³ the Envision platform enhances the detection of subtle objects, minimizes focal spot blur and improves 3D image sharpness.^4,5,6*

“There is tremendous excitement surrounding our latest breast health innovations, and our team is looking forward to showcasing the many ways we’re advancing solutions across the breast health continuum at this year’s RSNA,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic. “Through strong customer relationships, continuous improvement and the latest research, we continue to take our leading technologies to the next level to support healthcare providers in improving the patient experience and providing excellent care.”

Further demonstrating its leadership in breast imaging AI, Hologic will also introduce its next-generation Genius AI^® Detection PRO solution for use in the United States. This advanced cancer screening technology expands on Hologic’s Genius AI Detection 2.0 solution by providing even greater accuracy and efficiency,⁷ giving radiologists more confidence and helping to reduce false positives.⁸ This new mammography AI assistant provides:

• A deep-learning 2D and 3D algorithm that improves specificity by using a patient’s prior exam in the current exam’s analysis.
• Intuitive 1-10 case and lesion scoring and pre-populated exam reports designed to accelerate image review and save radiologists’ valuable time.
• An all-in-one interface that conveniently includes deep-learning breast density scoring along with key patient and mammogram quality information, designed to support radiologists at every step of the reading workflow.

“With Genius AI Detection PRO, Hologic continues to lead the way in innovation for AI in breast imaging and cancer detection,” said Anderson. “By harnessing the latest advances in artificial intelligence and transformative workflow features, we continue to push the boundaries of science to revolutionize mammography and the future of women’s healthcare.”

On December 1 at RSNA, Hologic will also present the results of a recently published study demonstrating the performance of its Genius AI Detection 2.0 software across diverse patient populations. The study looked at more than 7,500 3D mammograms from women who identified as Asian, Black, Hispanic or white. Researchers found that the measured performance of the algorithm was similar across all cohorts evaluated,⁸ illustrating its ability to deliver results that are not impacted by racial bias. Reducing racial bias in AI algorithms is a growing concern in healthcare.

In the South Hall, Booth #1919 at McCormick Place, attendees can experience Hologic’s Dimensions^® mammography portfolio, Envision Mammography Platform, Genius AI Detection 2.0 and Genius AI Detection PRO software, Affirm^® Contrast Biopsy software, I-View^® Contrast Enhanced Mammography software and a full suite of breast biopsy and surgery solutions. The company will also showcase recently acquired Endomag wireless breast surgery localization and lymphatic tracing solutions, including the Magseed^® marker, the Magtrace^® lymphatic tracer and the Sentimag^® platform.

Additionally, Hologic will host several workshops including:

• Navigating Breast Localization: From Imaging to Surgery
  Sunday, Dec. 1: 11:45 a.m.-12:45 p.m. CST (Room S502)
  A panel discussion aiming to foster collaboration between radiologists and surgeons and discuss the latest advancements and best practices in breast localization to improve patient care and outcomes.
  

• Enhancing Breast Cancer Detection: The Role of AI in Mammography
  Tuesday, Dec. 3: 12-1 p.m. CST (Room S502)
  This presentation will delve into the transformative impact of AI on breast cancer detection. Speakers will discuss how AI technologies, particularly machine learning and deep learning algorithms, are enhancing the accuracy, speed and reliability of breast cancer screening processes.
  

• Innovative Advancements in Breast Cancer Screening: The Role of Contrast-Enhanced Mammography
  Wednesday, Dec. 4: 12-1 p.m. CST (Room S502)
  This presentation will explore contrast-enhanced mammography (CEM) in breast cancer detection. Speakers will talk about how CEM enhances traditional mammography by providing more detailed and accurate imaging, leading to improved diagnostic outcomes.

Finally, Hologic is proud to announce it was recently awarded the Excellence in Imaging Informatics Award by the American Board of Imaging Informatics (ABII), marking the first time an organization has been selected for this recognition. The award underscores the company’s commitment to providing not only the best early cancer detection technology, but also to serving as a valuable partner in imaging workflow and informatics integration. Hologic’s Certified Imaging Informatics Professionals (CIIPs) meet high standards of excellence set forth by the ABII, working with customers to design imaging workflow solutions to ensure the company’s technologies are easily integrated and maximized to provide better patient care.

To learn more about Hologic’s presence at RSNA 2024, please visit Hologic.com/RSNA.

About Hologic, Inc.

Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnosis and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Hologic, The Science of Sure, Dimensions, Envision, Genius AI, Genius AI Detection PRO, Genius AI Detection 2.0, I-View, LOCalizer, Magseed, Magtrace and Sentimag are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

References

*		Compared to the 3DimensionsTM Mammography System (3.7sec). DHM-05051_002.
1		Hologic data on file: VER-12082 (1.0).
2		Hologic data on file: DHM-16430.
3		FDA PMA Approval P080003/S009, 2024.
4		Hologic data on file: DHM-16158.
5		Hologic data on file: DHM-14517.
6		Smith, A. Tushita, P. Improving Tomosynthesis Image Quality using Advanced X-ray Technologies, Hologic WP-00300 (2024).
7		S. Pacilè, et al. (2024). Evaluation of a multi-instant multi-modal AI system supporting interpretive and noninterpretive functions. Accepted for publication in the Journal of Breast Imaging, https://doi.org/10.1093/jbi/wbae062.
8		K240301 510(k) summary distributed by Hologic, Inc.
9		Kshirsagar A, Smith, A. Reducing Bias in Breast Cancer Detection AI: Assessing the performance of Hologic’s Genius AI Detection Solution across different races and ethnicities, Hologic WP-00297 (2024).

SOURCE: Hologic, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125586668/en/

Media Contact

Bridget Perry

Senior Director, Corporate Communications

+1 508.263.8654

bridget.perry@hologic.com

Investor Contact

Ryan Simon

Vice President, Investor Relations

+1 858.410.8514

ryan.simon@hologic.com

Source: Hologic, Inc.

FAQ

What new products will Hologic (HOLX) showcase at RSNA 2024?

Hologic will showcase the Envision™ Mammography Platform and Genius AI® Detection PRO solution, along with their complete breast health portfolio at RSNA 2024.

What are the key features of Hologic's (HOLX) new Envision™ Mammography Platform?

The Envision™ Platform features a 2.5-second scan time, tilt positioning for patient comfort, and enhanced detection of subtle objects with improved 3D image sharpness.

How does Hologic's (HOLX) Genius AI® Detection PRO improve mammography screening?

Genius AI® Detection PRO improves specificity using deep-learning algorithms, provides 1-10 case scoring, pre-populated reports, and includes breast density scoring to accelerate image review and reduce false positives.